Viking Therapeutics Positions as High-Upside Challenger in Obesity Drug Market

Viking Therapeutics (VKTX) is emerging as a high-potential contender in the competitive obesity drug market, with Wall Street analysts projecting a consensus one-year price target of $93.59. This target represents a potential increase of over 170% from current trading levels, reflecting optimism surrounding the company's clinical pipeline. The weight-loss landscape is currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. While these GLP-1 based treatments have established a strong foothold, the market remains open to alternatives that can offer better patient outcomes or fewer side effects, providing an entry point for developers like Viking. Viking's lead candidate, VK2735, is a dual agonist targeting both GLP-1 and GIP receptors. In clinical trials for its weekly injectable form, the drug achieved an average weight loss of 14.7% within just 13 weeks, outperforming several existing options in the category. A primary differentiator for VK2735 is its tolerability profile. While users of current market leaders frequently report nausea and other gastrointestinal issues, Viking's injectable has demonstrated higher patient adherence and better tolerability during trials. The company is also advancing an oral version of the drug, which is currently in Phase 2 testing with Phase 3 trials expected to commence next quarter. However, the oral formulation has faced hurdles, with approximately one-third of participants discontinuing usage during Phase 2 testing due to adverse effects.